Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buying more Next week for Run to come. Good luck
ONCI = $$$$
http://www.ceregene.com/pipeline.asp
Mid-Stage ,,, possible AMBS MANF partner?
Could be a combination of MANF and another further along Neurotrophic Factor. this could be interesting
Following the Money here... Started a position here in NNAN
GL@ALL
Made a killing here last run up... Back on board with ONCI for the next LAUNCH
GL2ALL
How many people log in with this username of yours?
He answers my emails and linkedin messages.
Looks like u dont
Wrong Lympro has nothing to do with that. Do not twist it around
http://www.amarantus.com/diagnostic-development/lympro-alzheimers-disease-diagnostic-blood-test
Phase 2 ready. Furthest along AD test and should be 1st to market and top expert in AD Biomarkers is on board of advisors.
Lol sell. Ok. Not
Exaggerating. AMBS had the license to what they want. LymPro. 500 Milllion revenue per year potential
He replied within minutes maybe less than a minute
AMBS MANF MJFF
Buy and sit back.
Only stinks if you dont own it now
Who are you ?
BOL Please. No luck needed here.
BD and AMBS agreement. Would not take so long if was a simple lab contract. Folks AMBS has a partner for a lot more. Sit back and enjoy the ride.
You know its the same company right? check this link..
http://www.bd.com/ds/
AMBS & BD Diagnostics - makes sense to me
BD is mentioned more than once there.. I never said it was a done deal.. but I am willing to wager that BD is AMBS's new GLP Partner.
BD Diagnostics - located in Maryland ( remember this )
you actually sound like someone else... are you sure this is your only login here?
and PS you just showed up here... do your own DD before you question others DD on AMBS
This is the Chart that was Removed from Original AMBS LymPro White Paper.
[URL=http://imageshack.us/photo/my-images/19/whitepaperremovedchartb.png/][/URL]
Uploaded with [URL=http://imageshack.us]ImageShack.us[/URL]
http://img19.imageshack.us/img19/6140/whitepaperremovedchartb.png
AMBS 6.6 Timelines and Financial Projections
The Company is currently finalizing agreements with its projected GLP development partner, and is
preparing a detailed timeline with an associated financial model which it intends to make available in the
near future
Partner was leaked by accident in previous copy of White Paper
-------------> WWW.BD.COM
click on Lympro White paper in this section of AMBS website
http://ir.stockpr.com/amarantus/scientific-publications
Thanks for the headsup... Load up time.... on BEAC $$$$$$$$$$$$$$
nice Chart on CTIX, yes its clear that this is going to continue its upward trend
thanks for the DD... MARA is looking like another Winner ...$$$$$$$
This company has its stuff together.... they are making deals happen everywhere great sales and management staff at CPSZ
Adding TBIO Monday.... I believe this is gonna run.. Glad I was alerted to this Stock
AMGEN in the TBIO house only = $$$$$$$$$$$
good to see you here on TBIO also
Nice Chart on TBIO... looks like another GEM you have found
" 6.6 Timelines and Financial Projections
The Company is currently finalizing agreements with its projected GLP development partner, and is preparing a detailed timeline with an associated financial model which it intends to make available in the near future"
AMBS. Development Partner . Is pretty specific
And
Financial Model can mean milestone payments ?
Time will tell.
Good luck to ALL
The agreement being finalized with BD also involves the production of the actual blood test kits that would be sold for RUO and to pharma to help as CDx for orher AD drugs .They were mentioned in the original white paper under the Sales section of the graph.
This is a JV IMO. Time will only tell.
What did u post?
those others you mention don't have the License for LymPro like AMBS does... and LymPro is the furthest along AD Diagnostic test under development. This is one of the main reason they were able to recruit Dr. Adam J Simon to their board of advisers, he knows this as well
Dr. Adam J. Simon = he is one of the top experts in Bio-markers for AD.
Corporate Advisor
Dr. Simon is the founder and president of AJ Simon Enterprises, LLC, a consulting firm serving pharmaceutical and biotechnology clients, including Bristol Myers Squibb. He is also the founder and chief executive officer of Cerora, Inc., a healthcare information technology company focused on developing medical devices and services to assess brain health, including Traumatic Brain Injury. Earlier in his career he spent more than 13 years at Merck Research Laboratories, where he served as a Senior Research Fellow in Integrative Systems Neuroscience and Biomarkers and in Alzheimer’s disease research. He has also been a visiting scientist at Princeton University. Dr. Simon received Bachelor’s degrees in Physics and Mathematics from the University of Rochester. He received a Doctorate in Physics from the University of Chicago. He holds four patents related to medical research, and has published more than 60 articles in scientific and medical journals.
Where is my chart. AMBS should be called Lympro Gold Paper
PD patients would gladly take an Aspirin through the skull (CED proper term) GLADLY since it will bring them some normalcy .you don't understand this . AMBS is dedicated to this..
not to MJFF... they were given the official report from NEUROASSETS , hand delivered!
http://ir.stockpr.com/amarantus/company-news/detail/724/amarantus-posts-review-of-manf-literature-to-web-site
MANF displayed strong neuroprotective activity when administered to the striatum as evidenced by normalized ipsilateral rotational behavior evoked by amphetamine and protection of TH+ cell bodies in the substantia nigra.
· MANF prevented the striatal 6-OHDA-induced decrease of striatal dopaminergic terminals when administered to the substantia nigra.
· MANF’s activity is dependent on its location of administration and MANF’s effects manifest themselves distal to the administration site. Striatal administration of MANF protects nigral cell bodies while nigral administration of MANF protects striatal dopaminergic fiber densities.
· MANF may display effects contralateral to the growth factor administration site.
· MANF could be delivered to the striatum by convection enhanced delivery and MANF diffusion and distribution volumes could be measured by immunohistochemistry.
· Continued MANF development for the treatment of Parkinson’s disease is warranted based on the results of this present study, the known mechanism of action and published literature.